Eghbali Aziz, Bagherloo Tahereh, Ghasemi Ali, Afzal Roghayeh R, Eghbali Aygin, Ghaffari Kazem
Clinical Research Development Center of Aliasghar Hospital, Iran University of Medical Sciences, Tehran, Iran.
Department of Pediatric, Amir Kabir Hospital, Arak University of Medical Sciences, Arak, Iran.
Adv Biomed Res. 2023 Jun 28;12:158. doi: 10.4103/abr.abr_356_22. eCollection 2023.
In order to improve the complete recovery of nausea and vomiting, we conducted a study with the aim of preventing acute and delayed nausea and vomiting in children undergoing moderate emetogenic chemotherapy.
A clinical trial study was done on 130 children received chemotherapy. Patients received olanzapine and placebo. All groups received granisetron along with dexamethasone (DEX). The severity of chemotherapy-induced nausea and vomiting (CINV) induced by chemotherapy was compared in two groups.
The severity of nausea on the first, second, third, and fourth days was not significantly different ( > .05) in two groups. The number of patients without vomiting was significantly different during the first 24 hours after chemotherapy between patients in the two groups (82.3% vs 64.5%; = .016).
This study showed that olanzapine, which acts as an inhibitor of neurotransmitters, had a favorable efficacy in controlling acute and delayed CINV. More studies with large sample size are needed to compare the effect of olanzapine with other agents including aprepitant and palonosetron in the prevention of CINV.
为了提高恶心和呕吐的完全缓解率，我们开展了一项研究，旨在预防接受中度致吐性化疗的儿童出现急性和迟发性恶心及呕吐。
对130名接受化疗的儿童进行了一项临床试验研究。患者接受奥氮平和安慰剂治疗。所有组均接受格拉司琼联合地塞米松（DEX）治疗。比较两组化疗引起的化疗所致恶心和呕吐（CINV）的严重程度。
两组在第1、2、3和4天恶心的严重程度无显著差异（P>0.05）。两组患者化疗后24小时内无呕吐的患者数量有显著差异（82.3%对64.5%；P=0.016）。
本研究表明，作为神经递质抑制剂的奥氮平在控制急性和迟发性CINV方面具有良好疗效。需要更多大样本研究来比较奥氮平与其他药物（包括阿瑞匹坦和帕洛诺司琼）在预防CINV方面的效果。
